

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 March 2020 (26.03.2020)



(10) International Publication Number
WO 2020/061103 A1

(51) International Patent Classification:

C07D 519/00 (2006.01) A61K 31/5383 (2006.01)

A61P 35/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/051592

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(22) International Filing Date:

17 September 2019 (17.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

— with international search report (Art. 21(3))

(30) Priority Data:

62/733,061 18 September 2018 (18.09.2018) US

62/749,655 23 October 2018 (23.10.2018) US

62/810,911 26 February 2019 (26.02.2019) US

62/883,120 06 August 2019 (06.08.2019) US

62/883,121 06 August 2019 (06.08.2019) US

(71) Applicant: NIKANG THERAPEUTICS, INC. [US/US];
BLDG E400, 200 Power Mill Road, Wilmington, Delaware
19803 (US).

(72) Inventors: FU, Jiping; c/o Nikang Therapeutics, INC.,
BLDG E400, 200 Power Mill Road, Wilmington, Delaware
19803 (US). LOU, Yan; c/o Nikang Therapeutics, INC.,
BLDG E400, 200 Power Mill Road, Wilmington, Delaware
19803 (US). HE, Yigang; c/o Nikang Therapeutics, INC.,
BLDG E400, 200 Power Mill Road, Wilmington, Delaware
19803 (US).

(74) Agent: RICE, Janice V. et al.; Squire Patton Boggs (US)
LLP, 275 Battery Street, Suite 2600, San Francisco, Cali-
fornia 94111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS

(57) Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

WO 2020/061103 A1